Archives of Medical Research
Volume 41, Issue 1 , Pages 19-25.e1 , January 2010

Associations for Lipoprotein Lipase and Peroxisome Proliferator-activated Receptor-γ Gene and Coronary Artery Disease in an Indian Population

  • Manickaraj AshokKumar

      Affiliations

    • International Centre for Cardiothoracic and Vascular Diseases, Frontier Lifeline, Chennai, India
    • ,
  • Navaneethan Gnana Veera Subhashini

      Affiliations

    • International Centre for Cardiothoracic and Vascular Diseases, Frontier Lifeline, Chennai, India
    • ,
  • Sekar Kanthimathi

      Affiliations

    • International Centre for Cardiothoracic and Vascular Diseases, Frontier Lifeline, Chennai, India
    • ,
  • Ramineni SaiBabu

      Affiliations

    • International Centre for Cardiothoracic and Vascular Diseases, Frontier Lifeline, Chennai, India
    • ,
  • Arabandi Ramesh

      Affiliations

    • Department of Genetics, Dr. A. L. Mudaliar Postgraduate Institute of Basic Medical Sciences, University of Madras, Taramani Campus, India
    • ,
  • Kotturathu Mammen Cherian

      Affiliations

    • International Centre for Cardiothoracic and Vascular Diseases, Frontier Lifeline, Chennai, India
    • ,
  • Cyril Emmanuel

      Affiliations

    • Global Hospitals and Health City, Chennai, India
    • Corresponding Author InformationAddress reprint requests to: Dr. Cyril Emmanuel, Ph.D., Director, Research and Academics, Global Hospitals and Health City, Perumbakkam, Chennai-600100, India; Phone: +914422777000, +919444206238; Fax: +914422777100

Received 29 July 2009 ,Accepted 22 October 2009.

References 

  1. Ezzati M, Vander Hoorn S, Rodgers A, et al. Estimates of global and regional potential health gains from reducing multiple major risk factors. Lancet. 2003;362:271–280
  2. Reddy KS, Shah B, Varghese C, et al. Responding to the threat of chronic diseases in India. Lancet. 2005;366:1744–1749
  3. Lusis AJ, Mar R, Pajukanta P. Genetics of atherosclerosis. Annu Rev Genomics Hum Genet. 2004;5:189–218
  4. Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease. A statement for healthcare professionals from the American Heart Association. Circulation. 1999;100:1134–1146
  5. Blaschke F, Takata Y, Caglayan E, et al. Obesity, Peroxisome proliferator-activated receptor and atherosclerosis in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006;26:28–40
  6. Stein Y, Stein O. Lipoprotein lipase and atherosclerosis. Atherosclerosis. 2003;170:1–9
  7. Merkel M, Eckel RH, Goldberg IJ. Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res. 2002;43:1997–2006
  8. Lindi VI, Uusitupa MIJ, Lindström J, et al. Association of the Pro12Ala polymorphism in the PPAR-γ2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish diabetes prevention study. Diabetes. 2002;51:2581–2586
  9. Doney ASF, Fischer B, Leese G, et al. Cardiovascular risk in type 2 diabetes is associated with variation at the PPARG locus: a Go-DARTS study. Arterioscler Thromb Vasc Biol. 2004;24:2403–2407
  10. Anderson JL, King GJ, Bair TL, et al. Association of lipoprotein lipase gene polymorphisms with coronary artery disease. J Am Coll Cardiol. 1999;33:1013–1020
  11. Radha V, Mohan V, Vidya R, et al. Association of lipoprotein lipase HindIII and Ser447Ter polymorphisms with dyslipidemia in Asian Indians. Am J Cardiol. 2006;97:1337–1342
  12. Humphries SE, Nicaud V, Margalef J, et al. Lipoprotein lipase gene variation is associated with a paternal history of premature coronary artery disease and fasting and postprandial plasma triglycerides. The European Atherosclerosis Research Study (EARS). Arterioscler Thromb Vasc Biol. 1998;18:526–534
  13. Fajas L, Debril MB, Auwerx J. Peroxisome proliferator-activated receptor-γ: from adipogenesis to carcinogenesis. J Mol Endocrinol. 2001;27:1–9
  14. Michalik L, Auwerx J, Berger JP, et al. International union of pharmacology. LXI. Peroxisome proliferator activated receptors. Pharmacol Rev. 2006;58:726–741
  15. Doney ASF, Fischer B, Lee SP, et al. Association of common variation in the PPARA gene with incident myocardial infarction in individuals with type 2 diabetes: a Go-DARTS study. Nucl Recep. 2005;3:4
  16. Knouff C, Auwerx J. Peroxisome proliferator-activated receptor-γ calls for activation in moderation: lessons from genetics and pharmacology. Endocr Rev. 2004;25:899–918
  17. Semple RK, Chatterjee VKK, O'Rahilly S. PPARγ and human metabolic disease. J Clin Invest. 2006;116:581–589
  18. Nagy L, Szanto A. Roles for lipid-activated transcription factors in atherosclerosis. Mol Nutr Food Res. 2005;49:1072–1074
  19. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet. 2000;26:76–80
  20. Schneider J, Kreuzer J, Hamann A, et al. The proline 12 alanine substitution in the peroxisome proliferator-activated receptor-γ2 gene is associated with lower lipoprotein lipase activity in vivo. Diabetes. 2002;51:867–870
  21. Gerdes C, Gerdes LU, Hansen PS, et al. Polymorphisms in the lipoprotein lipase gene and their associations with plasma lipid concentrations in 40-year-old Danish men. Circulation. 1995;92:1765–1769
  22. Lahiri DK, Schnabel B. DNA isolation by rapid method from human blood samples: effects of MgCl2, EDTA, storage time and temperature on DNA yield and quality. Biochem Genet. 1993;31:321–328
  23. Mori H, Ikegami H, Kawaguchi Y, et al. The Pro12→Ala substitution in PPAR-γ is associated with resistance to development of diabetes in the general population. Diabetes. 2001;50:891–894
  24. Kuivenhoven JA, Groenemeyer BE, Boer JMA, et al. Ser447stop mutation in lipoprotein lipase is associated with elevated HDL cholesterol levels in normolipidemic males. Arterioscl Thromb Vasc Biol. 1997;17:595–599
  25. Tai ES, Corella D, Deurenberg-Yap M, et al. Differential effects of the C1431T and Pro12Ala PPARγ gene variants on plasma lipids and diabetes risk in an Asian population. J Lipid Res. 2004;45:674–685
  26. Radha V, Vimaleswaran KS, Babu HNS, et al. Role of genetic polymorphism peroxisome proliferator-activated receptor-2 Pro12Ala on ethnic susceptibility to diabetes in South-Asian and Caucasian subjects. Diabetes Care. 2006;29:1046–1051
  27. Larson I, Hoffmann MM, Ordovas JM, et al. The lipoprotein lipase HindIII polymorphism: association with total cholesterol and LDL cholesterol, but not with HDL and triglycerides in 342 females. Clin Chem. 1999;45:963–968
  28. Holmer SR, Hengstenberg C, Mayer B, et al. Lipoprotein lipase gene polymorphism, cholesterol subfractions and myocardial infarction in large samples of the general population. Cardiovas Res. 2000;47:806–812
  29. Reasner CA. Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors. J Cardiovasc Pharmacol. 2008;52:136–144

PII: S0188-4409(10)00006-8

doi: 10.1016/j.arcmed.2010.01.005

Archives of Medical Research
Volume 41, Issue 1 , Pages 19-25.e1 , January 2010

Article Tools

* Image Usage & Resolution